Novanta (NASDAQ:NOVT – Get Free Report) issued its quarterly earnings results on Tuesday. The technology company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.06, Zacks reports. Novanta had a return on equity of 15.20% and a net margin of 6.52%. During the same period in the prior year, the firm posted $0.74 earnings per share. Novanta’s revenue was up 1.1% on a year-over-year basis. Novanta updated its Q2 2025 guidance to 0.680-0.780 EPS.
Novanta Stock Down 3.0 %
NOVT stock traded down $3.59 during midday trading on Tuesday, hitting $116.43. 202,965 shares of the company’s stock were exchanged, compared to its average volume of 200,944. The firm has a 50 day moving average price of $125.50 and a 200-day moving average price of $147.12. Novanta has a 12-month low of $98.76 and a 12-month high of $187.12. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of 70.05 and a beta of 1.51. The company has a current ratio of 2.79, a quick ratio of 1.81 and a debt-to-equity ratio of 0.61.
Wall Street Analysts Forecast Growth
Separately, Robert W. Baird dropped their target price on shares of Novanta from $169.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd.
About Novanta
Novanta, Inc engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products.
Further Reading
- Five stocks we like better than Novanta
- Conference Calls and Individual Investors
- The Top-Ranked Insider Buys From April by Market Cap
- How is Compound Interest Calculated?
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
- 3 Stocks to Consider Buying in October
- Hims & Hers Stock Rises on Fundamentals and Squeeze Potential
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.